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Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect of several 
anti-neoplastics and a main cause of sensory disturbances in cancer survivors, negatively impacting 
patients’ quality of life. Peripheral nerve degeneration or small fibre neuropathy is generally accepted 
as the underlying mechanism in the development of CIPN. Recent evidence has contributed to clarify 
the determinant role of cytokines and chemokines in the process leading to neuronal hyperexcitability. 
Exposure to oxaliplatin triggers alterations in peripheral neuropathic pathways previously linked to IL-8 
pathway. We investigated a novel selective inhibitor of IL-8 receptors, DF2726A, and showed its effects 
in counteracting CINP pathways, extending the relevance of the activation of IL-8 pathway to the class 
of platinum chemotherapeutics. Based on our results, we suggest that DF2726A might be a promising 
candidate for clinical treatment of CIPN conditions due to its efficacy and optimized pharmacokinetic/
pharmacodynamic profile.
Chemotherapy-induced peripheral neuropathy (CIPN) is side effect of different anti-cancer drugs resulting in 
sensory illness in cancer patients, affecting the patients quality of life1,2. Chemotherapeutic agents associated with 
neurotoxicity are taxanes, platinum drugs, vinca alkaloids, thalidomide and bortezomib3. To date, no therapy 
exhists for preventing and treating CIPN1,4. Therefore, a deeper understanding of the pathophysiology of CIPN to 
better identify new pharmacological targets and more specific treatments is mandatory.
CIPN affects approximately 70% of patients receiving chemotherapeutic treatments, and its development 
is directly related to the specific drug or combination of anti-cancer agents used, dosing regimen, and clinical 
conditions2.
Clinically, CIPN is characterized by a series of sensory symptoms including paraesthesia and dysesthesia man-
ifested as numbness, tingling and altered touch perception as well as mechanical or thermal allodynia and hyper-
algesia5. Even if the causes of CIPN are not fully clarified, it is noteworthy that the overall neuropathic symptoms 
are quite similar for all the chemotherapeutic drugs such as taxanes, platinum, proteasome inhibitors, and vinca 
alkaloids. Peripheral neuropathy is generally recognized as the main mechanism in the development of CIPN6,7, 
but different reports indicate that neuropathic pain caused by anti-cancer drugs may develop as early as the first 
treatment in the absence of to intra-epidermal nerve fibres (IENFs) damage or peripheric axonal degeneration8,9.
Recent evidence has contributed to elucidate the determinant role of cytokines and chemokines in the pro-
cess leading to neuronal hyperexcitability. Exposure to chemotherapeutics such as paclitaxel10 and oxaliplatin7 
consistently increased secretion of pro-inflammatory cytokines (TNFα, IL-1β and IL-6) and downregulated 
anti-inflammatory cytokines (IL-10 and IL-4) in spinal astrocytes and dorsal root ganglia (DRGs), triggering 
alterations in peripheral neuropathic pathways.
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Paclitaxel was also associated with upregulation of Toll-like receptor 4 (TLR4) signalling, inducing higher 
expression of CCL211 as well as recruitment of macrophages and pro-inflammatory T cells in DRGs12. In addi-
tion, preclinical in vivo results showed CCL2 overexpression in paclitaxel-induced spinal astrocytes and DRGs13. 
Similarly, a very recent report described the induction of CCL2/CCR2 pathway in oxaliplatin-induced DRGs, 
increasing mechanical and cold allodynia, and hypersensitivity of spinal astrocytes14. Several other studies found 
that both paclitaxel and oxaliplatin induced analogous mechanisms in the pathogenesis of neuropathic pain 
including spinal astrocyte activation, loss of IENFs, and mechanical and cold hypersensitivity15–17.
We recently reported the efficacy of reparixin, an inhibitor of CXCR1/2, in paclitaxel-induced CIPN in rats, 
identifying the activation of the IL-8/CXCR1/2 axis as a mechanism strictly implicated in the induction and 
maintenance of paclitaxel induced-neuropathy. In the present study, we investigated a novel selective inhibitor 
of IL-8 receptors, DF2726A, suitable for chronic oral administration, extending the relevance of the activation of 
IL-8 pathway to the class of platinum chemotherapeutics. Based on our results, we suggest that DF2726A might 
be a promising candidate for clinical treatment of CIPN conditions due to its efficacy and optimized pharmacoki-
netic/pharmacodynamic profile.
Results
DF2726A in vitro characterization. The main in vitro pharmacological and physicochemical results are 
summarized in Table 1.
In vitro pharmacological characterization showed that DF2726A did not inhibit spontaneous human 
polimorphonuclear neutrophil (hPMN) migration per se, but was equally efficacious in inhibiting IL-8- and 
CXCL1-induced hPMN chemotaxis with IC50 values calculated in 10 ± 5 nM and 8 ± 3 nM for IL-8 and CXCL1, 
respectively.
Counterscreens demonstrated >100-fold selectivity for 55 targets among GCPRs, ion channels, enzymes and 
transporters (see Supplementary Informations).
DF2726A displayed excellent physicochemical and in vitro ADME properties, with good aqueous solubility 
and low lipophilicity. High plasma protein binding in three species (human, dog and rat) was observed with val-
ues higher than 94%. Furthermore, DF2726A showed excellent stability toward liver microsomes in human, dog 
and rat, no inhibition of selected CYP-enzymes involved in drug-drug interactions and no CYP-induction. The 
permeability in the Caco-2 cell assay was good with no P-glycoprotein (P-gp) inhibition. DF2726A exhibited no 
hERG inhibition in a patch-clamp assay (IC50 > 1 mM) and was devoid of potential cardiovascular liability. The 
compound did not show any in vitro genotoxiticy as demonstrated in the AMES Test. Finally, DF2726A did not 
inhibit COX-1 and COX-2 when tested at 50 µM.
Pharmacokinetic studies. Pharmacokinetic studies of DF2726A in Sprague Dawley rats showed a slow 
oral absorption (Cmax was reached at 6 h post dosing), high plasma exposure, a long half-life and low clearance 
(Table 2).
The oral elimination t1/2 of DF2726A was similar to intravenous elimination t1/2 (16.2 h vs 15.2 h). The rela-
tively low volume of distribution for DF2726A can be explained by the high plasma protein binding observed in 
the rat (97.5%).
Interestingly, DF2726A showed a very high bioavailability (96.8%) and a suitable pharmacokinetic profile for 
oral treatment.
DF2726A prevented oxaliplatin-induced peripheral neuropathy. Animals were treated according 
to the scheme illustrated in Fig. 1. Oxaliplatin-saline animals exhibited significative changes in paw withdrawal 
responses due to neurological toxicity.
Assay DF2726A
IC50 10 ± 5 nM (CXCL8) and 8 ± 3 nM (CXCL1)
Acqueous solubility >30 mg/mL
pKa/logD7.4/logP 4.14/0.75/4.3
Plasma protein binding (10 µM)
(human/dog/rat) 98.7%/94.8%/97.5%
Metabolic stability (human/dog/rat)
(Test conc: 2.5 µM, µL/min/106 cells 7.0/7.2/15.3
CYP Inhibition (IC50)
(1A2/2C9/2C19/2D6/3A4) >30 µM for all tested isoforms
CYP Induction (IC50)
(CYP2B6, 1A2, 3 A) >100 µM for all tested isoforms
Permeability (10 µM)
(A to B/B to A/Ratio/pH 6.5/7.4) 27.8/14.6/0.52
hERG (IC50, patch clamp) Negative (>1 mM)
AMES (100 µM) Negative
COX 1-2 Inhibition (50 µM) No Inhibition observed
Table 1. Physicochemical and in Vitro ADME Properties of DF2726A.
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Specifically, in DPA test, the paw withdrawal threshold of oxaliplatin-saline-treated animals appeared strongly 
reduced only at 14 and 21 days (**P < 0.01) after the first oxaliplatin treatment. DF2726A showed a significant 
anti-allodynic effect at 14 (#P < 0.05) and 21 days (##P < 0.01) (Fig. 2A).
In cold allodynia experiments, no paw withdrawal response was induced by acetone in control animals, indi-
cating that acetone-evoked cold stimulation is not noxious in non-neuropathic rats. Conversely, the paw with-
drawal threshold was significantly increased at all experimental time-points in oxaliplatin-saline-treated animals 
(Fig. 2B). In particular, animals treated with oxaliplatin-saline showed a significant, persistent cold allodynia from 
day 3 (*P < 0.05) to day 21 (***P < 0.001) post-initial oxaliplatin dosing. DF2726A treatment produced a marked 
attenuation of cold allodynia starting from day 5 (##P < 0.01) and persisting until the final test day (###P < 0.001) 
(Fig. 2B).
Intravenous
t1/2 (h) 15.2 ± 3.8
AUC0-last (μg/mL·h) 140.8 ± 24.9
Vd (L/kg) 0.52 ± 0.09
CLtotal (mL/min/kg) 0.62 ± 0.11
Oral
Cmax (µg/mL) 6.86 ± 1.6
tmax (h) 6.0
t1/2 (h) 16.2 ± 3.3
AUC0-last (μg/mL·h) 136.3 ± 22.6
F (%) 96.8
Table 2. Pharmacokinetic properties of DF2726A. Data represent the mean of concentrations in rat plasma 
(n = 3) following a single 5 mg/kg intravenous dose and 5 mg/kg oral dose.
Figure 1. DF2726A and oxaliplatin administration schematic in rats.
Figure 2. Time course of the effect of DF2726A on oxaliplatin-induced mechanical (A) and cold (B) allodynia. 
In control animals administered with oxaliplatin vehicle i.p. (CTR, black dots), the paw withdrawal responses 
remained unchanged during the whole experimental period. Rats treated with oxaliplatin (Oxa) + DF2726A 
vehicle (Oxa + saline, grey squares), showed marked changes in paw withdrawal responses. Administration of 
DF2726A (Oxa + DF, light grey triangles) was able to significantly reduce, oxaliplatin-evoked mechanical and 
cold allodynia. ***P < 0.001, **P < 0.01 and *P < 0.05 vs respective CTR group; ###P < 0.001, ##P < 0.01 and 
#P < 0.05 vs the respective Oxa + Saline group. 2-way repeated-measures ANOVA and Bonferroni test. Data are 
expressed as mean ± SEM; n 10 per group. ANOVA, analysis of variance.
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The beneficial effect of DF2726A was not limited to the oxaliplatin-induced CIPN model; paclitaxel-induced 
mechanical and cold allodynia in rats was also prevented by administration of DF2726A (Supplementary 
Informations: Suppl Fig. 1).
Moreover, the activation of microglia and astrocytes in DRG was analysed through the expression of Iba-1 
(Fig. 3) and GFAP (Fig. 3) by Western blot analysis. Results clearly showed a significant increase of both IBA-1 
and GFAP expression in oxaliplatin rats compared to sham group (*p < 0.05 and ***p < 0.001, respectively). 
DF2726A treatment significantly reduced the expression of both these markers (##p < 0.01 vs OXA rats).
Finally, we also evaluated TRPM8 and TRPA1 expression in DRG. Also in these case both ionic receptor 
channels were up-regulated in oxaliplatin rats if compared to sham group (***p < 0.001) (Fig. 3). A significant 
reduction in the expression of both receptors was induced by DF2726A treatment (#p < 0.5, ###p < 0.001 vs CTR, 
respectively).
DF2726A prevented oxaliplatin-induced loss of IENFs. Loss of IENFs was reported to play a criti-
cal role in the development of various neuropathies occurring in response to chemotherapeutic agents, such as 
oxaliplatin17. The immunofluorescence assay of PGP9.5 (a marker of IENFs) and collagen IV showed damage 
in IENFs extending from derma into epidermis in oxaliplatin-saline-treated compared to control rats (Fig. 4A). 
Interestingly, DF2726A treatment strongly counteracted this effect, preventing the loss of epidermal innerva-
tion (Fig. 4A). In addition, immunofluorescence assay showed that oxaliplatin treatment increased IL-8/CINC1 
signalling in the dermis. DF2726A treatment significantly attenuated this phenomenon, inducing a protective 
effect on nerve fibres (Fig. 4B). Lastly, anti-acetylated α-tubulin was evaluated in untreated, oxaliplatin- and 
DF2726A-treated nerve fibres. Immunofluorescence images showed that oxaliplatin treatment increased, even 
if not significantly, acetylated α-tubulin levels, while DF2726A completely restored control conditions (Fig. 4C). 
Taken together, these data show that oxaliplatin causes a pronounced decrease in IENFs, which was prevented by 
DF2726A administration.
Figure 3. Western blotting analyisis for microglia marker Iba-1 and for astrocyte GFAP in control, OXA and 
(Oxa) + DF2726A rats. In the bottom, TRPA1 and TRPM8 receptors in in control, OXA and (Oxa) + DF2726A 
rats, evalutated by western blotting. Administration of DF2726A (Oxa + DF, light grey triangles) was able 
to significantly reduce reactive microglia and astrocytes as well as to reduce pain receptors. ***P < 0.001, 
**P < 0.01 and *P < 0.05 vs respective CTR group; +++P < 0.001; ++P < 0.01 and +P < 0.05 vs the respective 
Oxa + Saline group. 2-way repeated-measures ANOVA and Bonferroni test. Data are expressed as mean ± SEM; 
n 10 per group. ANOVA, analysis of variance.
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In vitro models. The viability assay in neuronal cells after different treatments showed that oxaliplatin and 
DF2726A were ineffective in modulating neuronal cell viability at a concentration range of 5–60 µM and 5–20 µM, 
respectively (Supplentary Informations: Suppl Fig. 2). For the subsequent experiments, DF2726A was used at a 
final concentration of 1 µM, and oxaliplatin at a final concentration of 20 µM. For comparison, paclitaxel alone or 
in combination with DF2726A was also used. Paclitaxel was ineffective in modulating cell viability in the concen-
tration range 5–20 nM (Supplementary Informations: Suppl Fig. 2).
Acetylated α-tubulin (a marker of stable microtubules) was analysed by immunofluorescence in neurons after 
the different treatments. In untreated cells and in cells treated with DF2726A, acetylated α-tubulin was mod-
erately present. In contrast, both oxaliplatin and paclitaxel -treated neurons showed an increase in acetylated 
α-tubulin levels (Fig. 5 and Supplementary Informations: Suppl Fig. 3). Specifically, fluorescence intensity in neu-
rites was stronger, neurite diameter was greater, and cytoskeleton organization was more evident. Interestingly, 
acetylated α-tubulin in oxaliplatin + DF2726A-treated neurons was decreased compared to that in control con-
ditions, indicating that the presence of DF2726A counteracts chemotherapy-mediated effects (Fig. 5). The same 
effect was observed for paclitaxel + DF2726A treatment (Supplementary Informations: Fig. S3). In addition, we 
observed a greater thickness in paclitaxel-treated neurites compared to control, while under combined treatment 
with DF2726A cells appeared as control cells (Additional file 5: Suppl Fig. 3).
Acetylated α-tubulin was also investigated by western blotting. In agreement with morphological data, both oxalip-
latin and paclitaxel determined a marked increase in acetylated α-tubulin, while in combination with DF2726A the 
protein expression level was comparable to that of control cells (Fig. 5 and Suppl Informations: Suppl Fig. 3).
Figure 4. Effect of DF2726A treatment on oxaliplatin-induced intraepidermal nerve fibre loss. Representative 
images of immunofluorescence analysis and quantification of PGP9.5 (green, panel A), IL-8/CINC1 (green, 
panel B), acetylated a-tubulin (green, panel C) and collagen IV (red, panels A–C) in paw sections of rats from 
oxaliplatin vehicle group (CTR), oxaliplatin + DF2726A vehicle (Oxa + saline) and DF2726A-treated conditions 
(Oxa + DF). Nuclei are stained with DAPI (blue). **P < 0.005; ***P < 0.0005 vs CTR; +++P < 0.0005 vs Oxa, 
unpaired t-test. Data are expressed as mean ± SEM. n 5 per group. Bar = 75 μm.
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DF2726A counteracted oxaliplatin-induced neurotoxic pathways. We investigated the effect of 
DF2726A on expression of the active form of the protein of focal adhesion (p-FAK), which is responsible for 
microtubule stabilization. p-FAK levels were significantly increased by both oxaliplatin and paclitaxel treat-
ment, but decreased in the presence of DF2726A (Fig. 6 and Supplementary Informations: Suppl. Fig. 4). In 
addition, we analysed the active form of JAK2 (p-JAK2), involved in p-STAT3 signalling, which has a function in 
neuropathic pain and synaptic plasticity18,19. Both oxaliplatin and paclitaxel treatment increased p-JAK2, while 
combination with DF2726A restored control conditions (Fig. 6 and Supplementary Informations: Suppl. Fig. 4) 
p-STAT3 protein levels were also investigated in the different experimental conditions (Fig. 6 and Supplementary 
Informations: Suppl. Fig. 4). p-STAT3 levels increased after treatment with both chemotherapeutic agents com-
pared to control, while DF2726A counteracted this effect (Fig. 6 and Supplementary Informations: Suppl. Fig. 4). 
We also investigated PI3K/p-cortactin pathway, which plays a role in axonal arborisation and synaptic plasticity. 
Both oxaliplatin and paclitaxel strongly upregulated PI3K/p-cortactin expression, while combination treatment 
with DF2726A attenuated this effect (Fig. 6 and Supplementary Informations: Suppl. Fig. 4). All together, these 
data suggest a common pathway activated by both taxane and platinum agents, and that DF2726A is able to coun-
teract the effects of both drugs.
Activation of MAPK pathways is known to contribute to cellular damage. Oxaliplatin activates p38 and 
ERK1/2 and promotes apoptosis in DRG neurons20. In our experimental conditions, oxaliplatin strongly upregu-
lated the active form of ERK1/2 (p-ERK1/2) and increased PI3K and p-Akt, while in combination with DF2726A 
protein levels were comparable to those of control cells (Fig. 7). Lastly, oxaliplatin robustly upregulated COX2 
protein levels, while in combination with DF2726A COX2 expression levels were comparable to the control 
(Fig. 7).
Figure 5. Effect of DF2726A treatment on acetylated α-tubulin in oxaliplatin-treated neurons. 
(A) Representative images of acetylated α-tubulin (green) in control (CTR), oxaliplatin- (Oxa), 
Oxaliplatin + DF2726A and DF2726A-treated neurons analysed at confocal microscope. Nuclei are stained 
with DAPI (blue). Bar = 75 μm. (B) Representative blots probed for acetylated α-tubulin (right panel) and 
densitometric analysis (left panel) of acetylated α-tubulin in the same treatment conditions. **P < 0.005 vs 
control; +P < 0.05 vs Oxa, unpaired t-test. Data are expressed as mean ± SEM; n 3.
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Discussion
CIPN is a common adverse effect and the main dose-limiting toxicity associated with selected chemotherapeutic 
agents, including paclitaxel and oxaliplatin1. Although major efforts are now focusing on preventing the develop-
ment of taxane- and platinum-induced acute and delayed CIPN without impacting clinical outcomes, no drugs 
have yet been approved for prophylaxis and/or treatment of CIPN. Current therapeutic strategies are based on 
the continuous modification of chemotherapy regimens to manage the symptoms of devastating side effects and 
to improve patients’ quality of life.
Platinum compounds bind to nuclear DNA of cancer cells, leading to aberrant re-entry into cell cycle, apopto-
sis and tumour degradation. Paclitaxel and oxaliplatin are the two chemotherapeutics most frequently associated 
with the development of severe untreatable CIPN. Oxaliplatin, a third-generation platinum chemotherapeutic 
agent, causes severe acute and chronic peripheral neuropathies, including cold allodynia, loss of sensitivity and 
motor disturbances1,7,14. The pathophysiological mechanisms of paclitaxel- and oxaliplatin-induced neuropathy 
are not completely understood. However, a large body of evidence describes an associative and causal relation-
ship between activation of the immune system following taxane and platinum therapy and development of CIPN 
symptoms10,12. Several preclinical studies demonstrated that DRGs and spinal cord astrocytes treated with pacl-
itaxel and oxaliplatin display higher levels of pro-inflammatory chemokines and cytokines (CCL2, CCL3, TNF-α, 
IL-6, IL1β and IL-8), as well as decreased anti-inflammatory cytokine expression (IL-10 and IL-4), causing sensi-
tization of nociceptors, mechanical hyperalgesia and loss of IENFs16,17. A recent controlled clinical trial found an 
association between higher serum levels of pro-inflammatory cytokines and the severity of neuropathy induced 
by oxaliplatin in patients with colon cancer21. However, the exact mechanisms linking systemic cytokine and 
chemokine levels following chemotherapy with the development of CIPN symptoms remain to be elucidated.
Consistent with the above studies, our previous findings showed the significant effect of reparixin in atten-
uating the development of CIPN in sensitive neurons, suggesting a potential therapeutic role for chemokine 
inhibitors in prophylaxis and treatment of paclitaxel-induced CIPN22. We contributed to clarify the role of 
Figure 6. Effect of DF2726A treatment on oxaliplatin-induced neurotoxic signalling pathways in neurons. 
Representative blots of p-FAK, p-JAK2, p-STAT3, PI3K and p-cortactin and relative quantifications in 
control (CTR), oxaliplatin (Oxa)-, oxaliplatin + DF2726A (Oxa + DF)- and DF2726A (DF)-treated neurons. 
***P < 0.0005; **P < 0.005; *P < 0.05 vs control; +P < 0.05 vs Oxa, unpaired t-test. Data are expressed as 
mean ± SEM; n 3.
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paclitaxel-induced IL-8 expression as a trigger of the progressive neural toxicity mediated by activation of the 
pathways responsible for microtubule stabilization, axonal arborisation and synaptic plasticity.
In the present study, we evaluated the efficacy of DF2726A, a novel optimized selective dual inhibitor of 
CXCR1 and CXCR2, in an oxaliplatin-induced neuropathic pain model, confirming the key role of these phar-
macological targets and the additional importance of pharmacokinetic/pharmacodynamic optimization. 
Importantly, this work also extended our mechanistic and pharmacological studies of the paclitaxel-induced 
model, showing that the mechanisms underlying the neurotoxicity of the two drugs, unrelated to their chemo-
therapeutic action, are largely conserved and imply a key involvement of IL-8 receptors.
As previously reported for reparixin22, we found that DF2726A acts as a non-competitive allosteric modulator 
of CXCR1/2. DF2726A is a potent dual inhibitor of CXCR1/2 (IC50), with a good cross-reactivity versus rat and 
mouse, and an optimal selectivity profile versus a large panel of unrelated receptors. In line with the objectives of 
the lead optimization program, DF2726A exhibited improved features compared to reparixin, such as a longer 
half-life (16.2 h vs 1.78 h p.o. administration), a reduced plasma protein binding and better oral bioavailability. 
The optimization of the pharmacokinetic/pharmacodynamic profile was found to be associated with greater in 
vivo efficacy of DF2726A compared to that previously reported for reparixin in counteracting the increased sen-
sitivity to tactile and cold stimuli induced by oxaliplatin and paclitaxel. The results reported here describe for 
the first time the efficacy of CXCR1/2 inhibition in in vivo models of oxaliplatin-induced peripheral neurop-
athy. DF2726A administration in rats afforded an attenuated level of behavioural hypersensitivity, suggesting 
that IL-8 signalling contributes to both taxane- and platinum-induced CIPN. In line with the in vivo effects, we 
observed that oxaliplatin led to a strong decrease in the number of IENFs, which was significantly counteracted 
by DF2726A. Although the exact mechanism of epidermal denervation is poorly understood, some studies sug-
gested that it is linked to both paclitaxel- and oxaliplatin-induced neurological toxicity17,23, and is associated with 
increased levels of multiple pro-inflammatory cytokines10,14,23. Interestingly, we showed that IENF loss corre-
sponds to a local increase in IL-8 induced by oxaliplatin, and that DF2726A treatment strongly attenuated this 
phenomenon, suggesting its important protective role in nerve fibres.
In order to dissect the signal transduction pathways underlying the function of DF2726A in alleviating both 
paclitaxel- and oxaliplatin-induced neuropathic pain, we assessed the effects of IL-8 signalling in DRG-derived 
neuron cultures. In cancer, alterations in microtubule stability, including acetylation of tubulin, are reported to 
influence cellular responses to chemotherapeutics, tumour development, cellular trafficking and survival22,24,25. 
Although not classified as anti-microtubule agents, platinum compound agents are also associated with the 
Figure 7. Effect of DF2726A treatment on p-ERK1,2, p-Akt and COX2 in oxaliplatin-treated neurons. 
Representative blots of p-ERK1,2, p-Akt and COX2 and the relative quantifications in control (CTR), oxaliplatin 
(Oxa), oxaliplatin + DF2726A (Oxa + DF) and DF2726A (DF)-treated neurons. **P < 0.005 vs control; 
++P < 0.005, +P < 0.05 vs Oxa, unpaired t-test. Data are expressed as mean ± SEM; n 3.
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alteration of assembly processes and signalling functions of tubulin, as well as changes in cytoskeletal and axonal 
functions, all of which lead to neurotoxicity3,25–27. It was previously reported that DRG neurons express IL-8 
receptor22. We investigated the effect of DF2726A inhibition on both taxane- and platinum-induced tubulin 
acetylation in DRG-derived neurons. In our experimental conditions, both paclitaxel and oxaliplatin determined 
an increase in α-acetylated tubulin in DRGs, an effect efficiently counteracted by exposure to DF2726A. Under 
both paclitaxel and oxaliplatin treatment, DRG-derived neurons expressed higher levels of p-FAK responsible for 
microtubule stabilization, and activated the PI3K/p-cortactin pathway, leading to terminal axonal arborisation 
and synaptic plasticity. Additionally, paclitaxel and oxaliplatin exposure increased expression of p-JAK2, thereby 
triggering p-STAT3, known to have a function in neuropathic pain and synaptic plasticity. In line with our previ-
ous findings22, we demonstrated that CXCR1/2 inhibition by DF2726A is effective in reducing p-STAT3, p-FAK 
and PI3K/p-cortactin activation induced by both taxane and platinum agents, by modulating pivotal markers of 
chemotherapy-associated neurotoxicity. The activation of COX2 and ERK1/2 pathways can further contribute to 
cellular damage and neuropathic pain20,28,29. Oxaliplatin treatment was reported to induce peripheral neuropathy 
by triggering the COX2 and p-ERK1/2 cascade pathways20,28,30. Notably, our study corroborated these findings 
and showed that DF2726A significantly reduces COX2 and p-ERK1/2 protein expression by counteracting their 
oxaliplatin-induced activation, thus suggesting a pivotal role for CXCR1/2 in activating the COX2/ERK cascade.
Our findings show that IL-8 and its receptors CXCR1/2 are critically involved in the development of neu-
rotoxic activity associated with both paclitaxel and oxaliplatin treatment in DRGs, and CXCL8 blocking by 
DF2726A significantly counteracts their effects in vitro and in vivo.
Taken together, the results of our mechanistic studies suggest that IL-8 expressed in peripheral neurons may 
trigger a neuro-inflammatory reaction, resulting in a progressive neural sensitization via activation of key path-
ways involved in microtubule stabilization, terminal axonal arborisation and synaptic plasticity, and that the pro-
gressive accumulation of IL-8 may be partially responsible for the progressive epidermal denervation associated 
with chemotherapeutic treatments.
In summary, we show for the first time in a model of both paclitaxel- and oxaliplatin-related CIPN that the 
activation of IL-8 signalling is involved in the development of peripheral neuropathies, and that interfering with 
this signal using the novel compound DF2726A may be a useful strategy to alleviate chemotherapy-induced 
neurotoxicity.
Methods
For the in vitro pharmacological-physicochemical characterization and pharmacokinetic studies of DF2726A see 
Supplementary Informations.
Animals. Behavioural tests were performed on male Wistar rats (200–250 g, Harlan, Italy) housed in the 
animal care facility at the Department of Pharmacy of the University of Naples Federico II, Italy, as previously 
described22. Animals were housed, in a group of five, in a room with controlled temperature (22 ± 1 °C), humidity 
(60 ± 10%) and light (12 h per day); food and water were available ad libitum. All animals were weighted on the 
day of each treatment. All behavioural tests were performed between 09:00 and 17:00 h, and the animals were 
used only once. Animal care and manipulations were conducted in conformity with International and National 
law and policies (EU Directive 2010/63/EU for animal experiments, ARRIVE guidelines, and the Basel declara-
tion including the 3R concept). The procedures reported here were approved by the Institutional Committee on 
the Ethics of Animal Experiments (CVS) of the University of Naples Federico II and by Ministero della Salute 
under protocol no. 2014-00884607. Rats were randomized and divided into equal-size groups (n = 10 group) 
not predetermined by a statistical method. After completion of experiments, animals were sacrificed by cervical 
dislocation.
Drug administration. DF2726A was dissolved in saline and administered at the dose of 30 mg/2 ml/kg/os 
for 24 consecutive days starting 3 days before oxaliplatin administration and continuing for a further 21 days after 
the first administration of oxaliplatin. During this period, the compound was given 2 h after oxaliplatin treatment. 
For the drug administration regimen with paclitaxel, see Additional file 2.
Induction of neuropathy by oxaliplatin. Rats received i.p. injections of oxaliplatin (Tocris) (2.4 mg/kg/
day) or vehicle (5% glucose, 0.5 mL/rat), administered for 5 consecutive days every week for 3 weeks as described22.
Behavioural testing was performed prior to oxaliplatin/vehicle administration (day -1), as described in22 in 
order to determine the basal values of mechanical and cold nociceptive thresholds, and again on 3, 5, 7, 10, 14 
and 21 days following oxaliplatin/vehicle injection as shown in Fig. 1. For induction of neuropathy induced by 
paclitaxel, see Supplementary Informations.
Mechanical allodynia. To assess for changes in sensation or in the development of mechanical allodynia, 
sensitivity to tactile stimulation was measured using the Dynamic Plantar Aesthesiometer (DPA, Ugo Basile, 
Italy), which is an automated version of the von Frey hair assessment22. Animals were individually placed in 
Plexiglas boxes (30 × 30 × 25 cm) with a mesh metal floor covered by a plastic dome that enabled the animal to 
walk freely, but not to jump. When a trial is initiated, the device raises the filament to touch the foot and progres-
sively increases force until the animal withdraws its foot, or until it reaches a maximum of 50 g of force (cut-off). 
The DPA automatically records the force at which the foot is withdrawn. This test does not require any special 
pre-training, but just an acclimation period to the environment and testing procedure. Each paw was tested twice 
per session and the test was performed on both paws on the day before (day -1) and then 3, 5, 7, 10, 14 and 21 
days after first administration of oxaliplatin or vehicle. No consistent left and right differences were observed. The 
means of paw withdrawal (expressed in grams) were calculated from an average of four separate measurements. 
For assessment of mechanical allodynia using paclitaxel, see Additional File 2.
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Cold allodynia. Cold sensitivity was measured as the number of foot withdrawal responses after appli-
cation of acetone to the dorsal surface of the paw8,22. Animals were individually placed in Plexiglas boxes 
(30 × 30 × 25 cm). A drop of acetone (25 μL) was applied to the dorsal surface of paws with a syringe connected 
to a thin polyethylene tube while the rats were standing on a metal mesh. A brisk foot withdrawal response, after 
the spread of acetone over the dorsal surface of the paw, was considered as a sign of cold allodynia. The procedure 
was repeated three times at 5 min intervals on both paws. The mean of paw withdrawal (expressed in numbers) 
was determined from an average of six separate measurements. Cold responses were measured before (day -1) 
and then 3, 5, 7, 10, 14 and 21 days after first administration of oxaliplatin or vehicle. No consistent left and right 
differences were observed. For assessment of cold allodynia using paclitaxel, see Additional File 2.
Immunohistochemistry. Animals were sacrificed and a biopsy (3 mm) was taken from pad of the right 
hind paw. Biopsies were immediately placed in Zamboni’s fixative, where they were left at 4 °C. Tissues were then 
transferred to 20% sucrose for at least 24 h and used for immunohistochemistry analysis. Specimens were frozen 
in Optimal Cutting Temperature compound (OCT, Sakura Finetek Inc, CA, USA) and sliced into 20 μm thick 
serial coronal sections by cryostat AMES LAB-TEK (Westmont, Illinois, USA).
In brief, sections were blocked with phosphate buffer saline (PBS) containing 10% (Bovine Serum Albumin) 
and 0.3% Tween-20, for 1 h at RT and incubated, overnight at 4 °C, with the primary antibodies: IL-8 (mouse, 
1:25, R&D Systems Inc. Minneapolis, MN, USA), PGP9.5 (rabbit, 1:1000, AbD Serotec, NC, USA), acetylated 
alpha tubulin (mouse, 1:250, Abcam Cambridge, MA, USA) and collagen IV (goat, 1:25, Southern Biotech, 
Birmingham, AL, USA). Sections were then rinsed in PBS several times before incubation for 2 h at RT with 
secondary antibodies, donkey AlexaFluor 488 anti-rabbit or donkey AlexaFluor 633 (1:2000), goat anti-mouse 
conjugated with Alexafluor 488 (1:2000; Life Technologies, Camarillo, CA, USA). After extensive washing, cover-
slips were mounted with Vectashield mounting medium with DAPI (Vector Laboratories Burlingame, CA, USA) 
and then observed at a Leica TCS SP5 confocal microscope (Leica, Mannheim, Germany)31.
Quantification. Five slices were examined for each animal. For each slide, 4 fields were counted. For quanti-
tative evaluation of IL-8/CINC-1 (the homolog of IL-8 in rat) and PDG95, photomicrographs for each condition 
were analysed by ImageJ software (National Institutes of Health, Bethesda, MD, USA) as previously described31. 
Briefly, the pictures were converted into grey scale, and arbitrary units were assigned: 0 = black (i.e. absence of 
signal) and 255 = white. The signal was first measured on the tissue in an area devoid of signal at visual inspection 
and assumed as background; the threshold was then set at 1.5 times the background and the surface area and 
mean grey intensity were measured for all areas above the threshold. To obtain the signal intensity (in arbitrary 
units), the background was subtracted from the mean grey intensity and the result was multiplied by the surface 
area above threshold. This value was divided by the surface area of tissue section to calculate the signal intensity 
per unit surface area.
Cell culture and drug treatments. F11 hybridoma cells (ECACC 08062601), chosen as a model of DRG 
neurons22,32,33 were cultivated in DMEM (Euroclone, Milan, Italy) supplemented with 10% FBS (Sigma-Aldrich, 
St. Louis, MO, USA), 1% penicillin/streptomycin (Euroclone, MI, Italy) and 1% glutamine (Euroclone) at 37 °C, 
in humidified 95% air with 5% CO2 atmosphere. For all the experiments, cells were used at 18th passage. For 
immunofluorescence analysis, cells were seeded on coverslips at 1 × 104 cells/cm2 for 24 h. Cells were then differ-
entiated with rat NGF (rNGF; Sigma-Aldrich). rNGF was dissolved in DMEM with 1% penicillin/streptomycin 
and 1% glutamine (FBS free) at a final concentration of 50 ng/ml. Medium was replaced every 3 days until com-
plete differentiation, which occurred after 7 days.
Following neuronal differentiation, neurons were treated for 24 h with DF2726A (1 μM final concentration), 
oxaliplatin (Sigma-Aldrich; 20 µM final concentration), or the combination of the two molecules.
DF2726A stock solution (4.3 mM) was prepared freshly by dissolving 1.5 mg of DF2726A in 1 ml PBS, 20 µl 
NaOH 1 N and 30 µl HEPES 1 M.
Oxaliplatin stock solution (40 mM) was prepared by dissolving the powder in DMSO, and aliquots were stored 
at -20 °C. For cell treatment with paclitaxel, see Additional File 2.
Immunofluorescence. Cells were fixed in 4% paraformaldehyde in PBS for 20 min at RT and permeabilized 
in methanol for 5 min at −20 °C. Cells were then blocked with PBS containing 4% BSA for 30 min and incubated 
with the following primary antibody diluted in the blocking solution overnight at 4 °C: rabbit acetylated α-tubulin 
(1:4000; Cell Signaling Technology, Inc., Danvers, MA, USA), as previously described22,33. Cells were then rinsed 
in PBS several times before incubation with secondary antibodies: goat anti-rabbit conjugated with Alexafluor 
633 (1:2000; Life Technologies, CA, USA) for 30 min at RT. After extensive washing, coverslips were mounted 
with Vectashield mounting medium (Vector Laboratories Burlingame, CA, USA) with DAPI and then observed 
at a Leica TCS SP5 confocal microscope (Leica).
Western blotting. Animals were sacrificed and dorsal root ganglia (DRG) (L4-L6) were removed and stored 
at 80 °C. They were homogenized on ice-cold lysis buffer [20 mM Tris–HCl (pH 7.5), 10 mM NaF, 150 mM NaCl, 
1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, leupeptin and trypsin inhibitor 10 μg/
mL; 20 µl/sample, as previously described34.
After 1 h, tissue lysates were obtained by centrifugation at 20,000 g for 15 min at 4 °C. Protein concentrations 
were estimated by the Bio-Rad protein assay using bovine serum albumin as standard.
DRG lysate proteins (30 μg) were dissolved in Laemmli sample buffer, boiled for 5 min, and separated on 
SDS-polyacrylamide gel elctrophoresis and transferred onto nitrocellulose membrane (240 mA for 40 min at 
room temperature). The filter was then blocked with 1 × PBS and 3% non-fat dried milk for 40 min at room 
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temperature and probed with anti-Glial Fibrillary Acidic Protein (GFAP) antibody (diluition 1.1000; cat.
no.Z0334, Dako), anti-ionized calcium-binding adapter molecule 1 (Iba-1) antibody (dilution 1:1000; cat. no.019-
19741, Wako), anti-transient receptor potential ankyrin 1 (TRPA1) antibody (diluition 1:1000; cat. no. NB110-
40763, Novus Biologicals) and anti- Transient receptor potential M8 (TRPM8) antibody (diluition 1:10100; cat. 
no. NBP1-97311, Novus Biologicals) in 1 × PBS, 3% non-fat dried milk, and 0.1% Tween 20 at 4 °C overnight. The 
secondary antibody was incubated for 1 h at room temperature. Subsequently, the blot was extensively washed 
with PBS, developed using enhanced chemiluminescence detection reagents (Amersham Pharmacia Biotech, 
Piscataway, NJ, USA) according to the manufacturer’s instructions, and the immune complex visualized by Image 
Quant (GE Healtcare, Milan, Italy). The protein bands were scanned and densitometrically analyzed with a model 
GS-700 imaging densitometer (Bio-Rad Laboratories, Milan, Italy). To ascertain that blots were loaded with equal 
amounts of protein lysates, they were also incubated in the presence of the antibody against the β-actin protein 
(Sigma-Aldrich, Milan, Italy).
Control and treated cells were collected and lysed in ice-cold RIPA buffer (PBS pH 7.4 containing 0.5% sodium 
deoxycolate, 1% Igepal, 0.1% SDS, 5 mM EDTA, 1% protease and phosphatase inhibitor cocktails; Sigma-Aldrich) 
as described in22,33. Protein lysates (30 μg) were separated on 8–12% SDS-polyacrilamide gel and electroblot-
ted onto polyvinyldifluoride membrane (PVDF; Sigma-Aldrich). Nonspecific binding sites were blocked by 5% 
non-fat dry milk (Bio-Rad Laboratories, Hercules, CA, USA) in Tris buffered saline (TBS: 20 mM Tris- HCl, 
pH 7.4, containing 150 mM NaCl) for 30 min at RT. Membranes were then incubated overnight at 4 °C with the 
following primary antibodies, diluted with TBS containing 0.1% Tween 20 (TBS-T) and 5% non-fat dry milk: 
rabbit acetylated α-tubulin (1:3000; Cell Signaling Technology), rabbit p-FAK (1:500; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), rabbit p-JAK2 (1:500; Santa Cruz Biotechnology), rabbit PI3K (1:500; Abcam, Cambridge, 
UK), rabbit p-cortactin (1:1000; Abcam), goat p-STAT3 (1:200; Santa Cruz Biotechnology), rabbit p-Akt (1:1000; 
Immunological Sciences, Rome, Italy), goat COX2 (1:500; Santa Cruz Biotechnology), p-ERK1/2 (1:500 Santa 
Cruz Biotechnology). As secondary antibodies, peroxidase-conjugated anti-rabbit or anti-mouse IgG (1:10000; 
Vector Laboratories) and anti-goat (1:1000; Santa Cruz Biotechnology) were used. Immunoreactive bands 
were visualized by Pierce ECL Substrate (ThermoFisher Scientific, Waltham, MA, USA), according to the 
manufacturer’s instructions. The relative densities of immunoreactive bands were determined and normalized 
HRP-conjugated β-actin, using ImageJ software. Values were given as relative units (RU).
Statistics. For the in vivo results, all data were presented as mean ± SEM. Data analysis was performed using 
GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA). The significance of differences between groups 
was determined by two-way analysis of variance (ANOVA) followed by Bonferroni post hoc tests for multiple 
comparisons. The level of significance was set at P < 0.05.
For the in vitro and ex vivo results (rat paw), data were expressed as mean ± SEM. Statistical analysis was per-
formed by Student’s unpaired t test. The level of significance was set at P < 0.05.
Ethics approval and consent to participate. The procedures reported for animal use were approved by 
the Institutional Committee on the Ethics of Animal Experiments (CVS) of the University of Naples Federico II 
and by Ministero della Salute under protocol no. 2014-00884607.
Data Availability
The datasets used and/or analysed during the current study are available from the corresponding author on rea-
sonable request.
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